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Abstract
Van Rheenen RWJ, Glaudemans AWJM, Hazenberg 
BPC.  Whole body amyloid deposition imaging by 
123I-SAP scintigraphy 
Amyloidosis is the name of a group of diseases 
characterized by extracellular deposition of amyloid fibrils. 
Deposition of amyloid can be localized or systemic. The 
123I-SAP-scan can be used to image extent and distribution 
of amyloid deposition in patients with systemic AA, 
AL and ATTR amyloidosis. Images are assessed in a 
semi-quantitative way by comparing each organ directly 
or indirectly to the normal blood-pool distribution. 
Considerable variation is observed between the findings 
on 123I-SAP-scan and clinical manifestations of organ 
disease. Regardless, the 123I-SAP-scan still provides both 
an impression of specific organ involvement as well as a 
global view of the amyloid load of the whole body. Due to 
physiological uptake of iodine degradation products in the 
stomach or to overwhelming uptake in an enlarged liver or 
enlarged spleen, visualization of abdominal organs nearby 
is not always easy and sometimes even impossible. In 
these cases SPECT (/CT) provides additional anatomical 
information to enable a more reliable assessment of such 
an organ. 
Tijdschr Nucl Geneesk 2011; 33(4):785-791  
    
Introduction
Amyloidosis is the name of a group of diseases characterized 
by extracellular deposition of amyloid fibrils. This deposition 
can be localized (restricted to one organ or site of the body) or 
systemic (in various organs and tissues throughout the body). 
The clinical manifestations and diagnostic challenges will be 
described in another paper in this special issue.
Several types of amyloidosis can be identified by the type 
of protein involved. The three most important systemic 
types are: Amyloid A (AA) amyloidosis, immunoglobulin 
light chain-associated (AL) amyloidosis and transthyretin-
associated (ATTR) amyloidosis. These types all have a different 
underlying pathology and clinical presentation. AA amyloidosis 
is associated with longstanding inflammatory disorders; its 
predominant clinical feature is nephropathy. In AL amyloidosis 
the underlying cause is a free light chains-producing 
monoclonal plasma cell dyscrasia; it has very diverse clinical 
manifestations. ATTR amyloidosis may be mutation-related 
(hereditary) or age-related (senile). The hereditary form is 
associated with mutations of the transthyretin (TTR) gene and 
its main manifestations are neuropathy and cardiomyopathy 
(1). The senile form is associated with non-mutated wild-
type TTR and its main manifestation is a slowly progressive 
cardiomyopathy.
Histological proof remains the gold standard for the diagnosis 
of amyloidosis (2), but is sometimes difficult to obtain, is an 
invasive procedure and is subjected to sampling errors. Several 
diagnostic and laboratory tests are available to measure organ 
function indirectly. However, direct measurement of amyloid 
burden in the body is not available. Currently, the best whole 
body imaging method is the labelling of Serum amyloid P 
component (SAP) with radioactive 123iodine (123I-SAP). This 
nuclear imaging technique is used to image the extent and 
distribution of amyloid deposition in patients with all types 
of amyloidosis (3-7) and has nowadays an important role 
in the diagnosis and follow-up of patients with (suspected) 
amyloidosis.
This overview article highlights the different aspects of 123I-SAP 
scintigraphy, from the tracer characteristics and the acquisition 
parameters to the interpretation, patterns, prognostic value and 
clinical relevance.
Tracer characteristics
In the human body SAP is produced only by hepatocytes, and 
the plasma concentration seems to be regulated at a rather 
constant level, even during deposition of SAP into amyloid. 
This indicates that the synthesis of SAP can be increased 
dramatically (4). The normal function of SAP is not known. All 
types of amyloid bind in a calcium-dependent manner to SAP, 
and therefore it is a suitable tool to be used for the imaging of 
all types of amyloidosis (8). Furthermore there does not seem 
to be such an interaction between SAP and normal tissue (9). 
In healthy individuals SAP is mainly located in the plasma 
compartment, from which it is metabolized and excreted by 
the liver, with a half-life of about 24 hours (4). In patients with 
systemic amyloidosis the total amount of SAP associated with 
amyloid is many times higher than the total amount in the 
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plasma compartment of healthy individuals. During all phases 
of amyloid deposition and metabolism there is a constant 
exchange of SAP between the two compartments (figure 1) 
(10). 
For the tracer production SAP has been isolated and purified 
from plasma of healthy donors. N-bromosuccinimide is used 
to oxidatively label the SAP protein with 123I, while preserving 
its normal function (10). The molecule characteristics and the 
half-life of 123I (13.2 hours) make it a very suitable radionuclide 
for amyloid imaging and, when labeled with high affinity to SAP, 
it is only metabolized in the liver. Radiolabeling methods and 
quality controls are performed as described (2).
Scintigraphy
Patients are intravenously injected with 200 MBq 123I-SAP. 
Uptake of free 123I in the thyroid is prevented by oral 
administration of potassium iodide. Scintigraphy is performed 
24 hours after injection, with a dual head gamma-camera 
(Siemens MULTISPECT 2, Hoffman Estates, Illinois), equipped 
with a medium energy all-purpose collimator. Anterior and 
posterior total body images (in running mode;10cm/min) are 
acquired simultaneously, followed by detailed simultaneously 
acquired anterior and posterior images (10 min) of the abdomen 
and a single photon emission computed tomography (SPECT) 
of the abdomen. If necessary, a low-dose CT of the abdomen is 
performed additionally to obtain anatomic details.
Image assessment
The images are assessed in a semi-quantitative way by 
comparing each organ directly or indirectly to the normal 
blood-pool distribution (table 1). Organ involvement is graded 
Figure 1. Schematic overview of biodistribution and metabolism of SAP in patients with systemic amyloidosis. Modified from 
reference 10
Table 1. Semi-quantitative score of uptake: overwhelming (3+), intense (2+), positive without any doubt (1+), weak or doubtful (+) 
and normal (-). Modified from reference 12
Organ View Visual assessment of abnormal uptake
Liver Anterior More than normal blood-pool in the heart.
Spleen Posterior / SPECT More than the liver. If liver is positive than similar uptake is abnormal.
Bone marrow Posterior Visible sacral bone, pelvis, long bones or individual vertebrae
Kidneys Posterior / SPECT More than vertebrae. If vertebrae are positive than similar uptake is abnormal.
Adrenal glands Posterior / SPECT One or both visible separate from kidneys, liver and spleen.
Joints Anterior / Posterior More than surrounding tissues.
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Figure 2. Clinical examples of semi-quantitative assessment of 123I-SAP-scan. Grading of organ involvement: overwhelming (3), 
intense (2), positive without any doubt (1) and normal (0)
3+ (overwhelming uptake), 2+ (intense uptake), 1+ (positive 
uptake without any doubt), ± (weak or doubtful) and – (normal) 
(11). Examples are shown in figure 2.
The following patterns may be observed and are typical for the 
different types of amyloidosis (12):
AA Amyloidosis: abnormal uptake in the spleen is •	
common. The three most frequent uptake patterns are: (1) 
abnormal uptake in the spleen only, (2) abnormal uptake 
in the spleen and kidneys, and (3) abnormal uptake in the 
spleen, kidneys and adrenal glands.
AL Amyloidosis: abnormal uptake in the spleen is •	
common. Uptake in other organs, such as liver, kidneys, 
bone marrow and joints, is very diverse.
ATTR Amyloidosis: Only abnormal uptake in the spleen or •	
kidneys is seen. 
In healthy individuals there is no organ deposition of 123I-SAP, 
and the tracer is then confined to the circulating blood pool and 
major blood organs (3, 13, 14). 
Because of the semi-quantitative nature of the assessment, 
the inter-observer variety may be high, and therefore in our 
center the images are assessed by two experienced clinicians 
(rheumatologist and nuclear medicine physician) who will reach 
consensus.
Clinical correlation and prognostic value
Clinical studies with 123I-SAP in patients with well-defined 
amyloidosis have shown a sensitivity of 100% in AA 
amyloidosis, 84% in AL amyloidosis and 95% in ATTR 
amyloidosis (10). The overall specificity is 93% (12).
123I-SAP-scans can serve as a clinical tool for evaluation of 
amyloidosis patients. During life it is impossible to obtain a 
quantitative impression of the amount of amyloid in the body 
by using other procedures. Even multiple biopsies from many 
organs would only provide a qualitative impression of the 
amount of amyloidosis and serial monitoring of vital organs 
and tissues by biopsies is impossible (2). By using 123I-SAP-
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Figure 3. Proteinuria and 123I-SAP kidney uptake. The dashed line indicates heavy proteinuria (>3.5 g/24h). Horizontal lines show 
median values. (A) AA patients. (B) AL patients. Reproduced with permission from reference 12.
scans it has become possible to obtain a (semi-) quantitative 
assessment of the amyloid load of specific organs, as well as 
a general impression of the total body amyloid burden thereby 
providing a more complete staging of the disease and a non-
invasive evaluation during and after therapy.
In clinical practice, however, the findings on a 123I-SAP-scan 
and clinical manifestations of disease vary considerably 
among organs. Increased uptake of spleen and liver can be 
seen before clinical disease is present. On the other side, 
kidney involvement is detected earlier by proteinuria or loss 
of function than by 123I-SAP-scintigraphy. Both heart and 
nerves are not visualized with this imaging method. Kidney 
uptake is concordant with severity of proteinuria (figure 3) and 
liver uptake in AL amyloidosis is concordant with increasing 
worst prognosis from patients in whom chemotherapy still may 
be beneficial (figure 4).
Furthermore uptake within the joints can be challenging in the 
assessment of a scan because of the false positive outcome in 
patients with arthritis, such as rheumatoid arthritis. Uptake of 
SAP in these cases is non-specific because of synovial effusion 
in arthritic joints due to the increased blood-pool at these sites.
As already stated above, the 123I-SAP-scan is not suitable for the 
evaluation of the heart, most likely due to lack of fenestrated 
endothelium in the myocardium (12). To determine amyloid 
burden of the heart, an indirect imaging method is available 
that measures the innervation of the heart (123I-MIBG). Further 
on, due to not crossing the blood-brain-barrier, 123I-SAP is not 
able to visualize amyloid plaques in the brain. In this situation 
imaging with 11C-PiB comes into sight. These two radionuclides 
are described elsewhere in this special issue.
Better Imaging; 123I-SAP SPECT 
Since the development of hybrid imaging systems, such 
as SPECT/CT, SPECT and CT images of the abdomen have 
been added to our routine imaging protocol of 123I-SAP. This 
obviously has substantial advantages.
On planar imaging physiological stomach uptake and an 
enlarged liver can obscure the visualisation of the spleen. At 
the same time the spleen (and an enlarged liver) can obscure 
visualisation of the kidneys and adrenal glands (1). Inaccurate 
information about organ involvement may have a negative 
effect on diagnosis, disease staging and follow-up of a 
patient with amyloidosis (1). Empirically it has been proposed 
that SPECT imaging should solve the problem of obscured 
visualisation of abdominal organs on a SAP scan. However, 
this issue has not yet been studied.
In our practice SPECT/CT has become a complementary 
modality next to the static planar images. Often physiological 
uptake in the stomach hinders accurate assessment of the 
spleen, but with SPECT/CT this problem can be addressed 
easily (figure 5). With regards to the adrenal glands it seems 
that SPECT/CT is the best way to assess involvement by 
giving accurate grading (figure 6). SPECT/CT of the abdomen 
is now routinely used in these patient groups and a patient 
study of the additional value of SPECT and CT has just been 
finished.
Conclusion
The 123I-SAP-scan is a non-invasive sensitive imaging 
modality to detect and grade amyloid deposits in most 
organs (except heart and brain) in patients with all types of 
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Figure 4. Survival of 80 patients with AL amyloidosis. (A) Patients with (dotted line) and without (solid line) clinical involvement 
of the heart. (B) Patients with high (>50%) (●) and low (<50%) (   ) tissue retention of SAP after 24 hours (EVR24). (C) Patients 
stratified according to high (>50%) (●) and low (<50%) (   ) EVR24 and presence (dotted line) or absence (solid line) of clinical 
involvement of the heart. Reproduced with permission from reference 11
amyloidosis. Although there is a high variety among individual 
patients, its use for diagnosis, disease staging and follow-
up in patients with amyloidosis makes it a valuable tool in 
the clinical management of patients with amyloidosis. The 
semi-quantitative assessment and sometimes obscured 
nearby abdominal organs by overlap can make accurate and 
consistent assessment difficult and sometimes impossible. 
However, this problem can be addressed by collaborative 
assessment and the use of SPECT/CT imaging. 
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serum levels of alkaline phosphatase. One should realise that 
individual variation is considerable (12). Amyloid deposition is a 
more dynamic process than previously thought, with a balance 
of deposition and removal that also differs among various 
tissues and organs with even some redistribution of amyloid 
(15). This possible redistribution of amyloid may partly account 
for a sometimes unpredictable course of the disease. It puts 
emphasis on not only assessing individual organ uptake, but 
also on assessing the total body load of amyloid.
In order to obtain an impression of the total body burden, blood 
and urinary samples are collected after one day to calculate the 
tissue retention of 123I-SAP. The percentage of tissue retention 
of SAP may sometimes help to diagnose amyloidosis. But, 
because of wide variation of the values, tissue retention of 
SAP does not reliably predict clinical stage or prognosis in 
the individual patient (11). In patients with AL amyloidosis, 
cardiac involvement is the most important predictor of survival. 
However, in this group of patients with cardiac involvement, 
tissue retention of SAP helps to distinguish patients with the 
Figure 5. (A) Planar SAP scan image (anterior / posterior) of a patient with AA Amyloidosis; the spleen is difficult to assess because 
of uptake in the stomach. (B) SPECT/CT images conclusively show physiological uptake in the stomach and positive uptake (1+) in 
the spleen.
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Figure 6. (A) Planar SAP scan image (anterior / posterior) of a patient with AA amyloidosis. The adrenal glands are difficult to 
assess. (B) SPECT/CT images show uptake in both adrenal glands
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